読み込み中
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
最新データ
$42.19
−$0.01 · -0.02%
日中の時刻はETです。市場データは遅延する場合があります。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
30
割高
センチメント
60
まちまち
リスク
29
中程度のリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 3319.3万 USD | 1881.6万 USD |
| 売上原価 | 2.08億 USD | 193.7万 USD | 284.4万 USD | 1.23億 USD | 1.08億 USD |
| 粗利益 | −2.08億 USD | −193.7万 USD | −284.4万 USD | −8985.1万 USD | −8965.2万 USD |
| 研究開発 | 2.08億 USD | 1.83億 USD | 1.19億 USD | 1.24億 USD | 1.08億 USD |
| 販売・一般管理 | 1.76億 USD | 6750.4万 USD | 4939.5万 USD | 4261.9万 USD | 4026.9万 USD |
| 営業費用 | 1.76億 USD | 2.5億 USD | 1.68億 USD | 4451.9万 USD | 4026.8万 USD |
| 受取利息 | 1390万 USD | 1268.2万 USD | — | — | — |
| 支払利息 | 689.3万 USD | 683.7万 USD | — | — | — |
| 減価償却費と償却費 | 165.8万 USD | 193.7万 USD | 284.4万 USD | 298.6万 USD | 262.7万 USD |
| 営業利益 | −3.85億 USD | −2.52億 USD | −1.71億 USD | −1.34億 USD | −1.3億 USD |
| 純利益 | −3.78億 USD | −2.46億 USD | −1.66億 USD | −1.35億 USD | −1.32億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.95億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1.24億0.16%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI7797.5万0.79%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF6567.84万0.07%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO4102.59万0.30%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO3650.5万0.20%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB3247.76万0.31%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA2294.48万0.11%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
